Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
City of Hope Medical Center
Novartis
AstraZeneca
Columbia University
ADC Therapeutics S.A.
National Cancer Institute (NCI)
Stanford University
Genzada Pharmaceuticals USA, Inc.
Provectus Pharmaceuticals
MacroGenics
Asana BioSciences
Abramson Cancer Center at Penn Medicine
University of Wisconsin, Madison
Sichuan Huiyang Life Science and Technology Corporation
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
City of Hope Medical Center
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Calando Pharmaceuticals
Altor BioScience
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center